HEADACHE CLINICAL TRIALS

TEVA48125-CNS-300049: Phase 3 Clinical Trial for Chronic Migraine

A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of chronic migraine.

This is a 5 month study. Participants must have 8 migraine days per month, and may be on 1 preventative medication for migraine. Participants will have the option of rolling into the 18 month long-term safety study

(NO LONGER ENROLLING)                                                                                 

TEVA48125-CNS-300050: Phase 3 Clinical Trial for Episodic Migraine

A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of episodic migraine.

This is a 5 month study. Participants must have 8 migraine days per month, and may be on 1 preventative medication for migraine. Participants will have the option of rolling into the 18 month long-term safety study            

(NO LONGER ENROLLING)

TEVA48125-CNS-30051: Phase 3 Clinical Trial for Migraine

A multicenter, randomized, double-blind, parallel-group study evaluating the long term safety, tolerability and efficacy of subcutaneous administration of TEVA-48125 for the preventive treatment of migraine.

This is the long-term 18 month rollover study from TEVA48125-CNS-300049 and TEVA48125-CNS-300050

(ROLLOVER STUDY)

ALLERGAN UBR-MD-02: Phase 3 Clinical Trial for Migraine

A multicenter, randomized, double blind, placebo controlled, single attack study to evaluate the efficacy, safety and tolerability of oral Ubrogepant in the acute treatment of migraine.

This study can last from 1-4 months to treat a single migraine attack.  Participants must have 2-8 migraine attacks per month, and can be on preventive migraine treatment if they are stable over the last 2 months. Participants will have the option of rolling into the 18 month long-term study

(ENROLLING NOW)

ALLERGAN UBR-MD-04: Phase 3 Clinical Trial for Migraine

A multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral Ubrogepant in the acute treatment of migraine with or without aura.

This is the long-term18 month rollover study from ALLERGAN UBR-MD-02

(ROLLOVER STUDY)

 

Principal Investigator for all clinical trials: Jessica Heiring, MD

Research Contacts:

Tracy Anderson, RN SC 763-302-4099
Katelynn Rehs, SC 763-302-4035